This study investigates advanced pancreatic adenocarcinoma. It focuses on the use of irreversible electroporation combined with an investigational medication to treat this condition.
The study evaluates the safety and effectiveness of this combined treatment approach. It looks at how well patients tolerate the treatment and its overall impact on the condition.
- Who can participate: Adults 18 years and older with stage III pancreatic cancer can join. Participants must have measurable tumors and meet specific health criteria.
- Study details: Participants will undergo irreversible electroporation and receive an investigational medication post-operatively. A placebo will not be used in this study.